{"id":11033,"date":"2020-03-15T10:07:35","date_gmt":"2020-03-15T04:37:35","guid":{"rendered":"https:\/\/www.rootsanalysis.com\/blog\/?p=11033"},"modified":"2026-07-30T21:54:45","modified_gmt":"2026-07-30T16:24:45","slug":"cell-therapy-manufacturing","status":"publish","type":"post","link":"https:\/\/www.rootsanalysis.com\/blog\/cell-therapy-manufacturing\/","title":{"rendered":"Cell Therapy Manufacturing: Here are the Key Innovations"},"content":{"rendered":"\n

Last week, during our weekly industry update sessions, our prime focus was to understand the recent innovations in the field of cell therapy manufacturing. We were also looking out for players that are driving these innovations. <\/p>\n\n\n\n

To start with, the first news that caught our attention was Novartis’ decision <\/a>to sidestep Europe travel ban to provide CAR-T cell therapy<\/a> Kymriah to patients. Amid the growing concerns regarding the rapid rise in COVID-19<\/a> cases, this decision by Novartis certainly comes as a much needed good news<\/em>.<\/p>\n\n\n\n

In this article, we will discuss some of the key innovations in cell therapy manufacturing that have caught the industry’s attention in the last few weeks.<\/p>\n\n\n\n

Cell Therapy Supply Chain<\/h2>\n\n\n\n

In one of our recent articles<\/a>, we talked about the strategies that cell therapy manufacturing companies<\/a> can adopt to improve the supply chain. Some of the players, such as (illustrative list)<\/em> Trakcel, Veeva, Be the Match BioTherapies have already deployed solutions efficiently manage and streamline various aspects of the complex supply chains of cell and advanced therapies. In fact, more than 160 innovative software-enabled systems have been developed for managing the cell and advanced therapies supply chain. The key supply chain challenges in cell therapies are:<\/p>\n\n\n\n